Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
-
Bristol Myers Squibb (NYSE:BMY) released Phase 4 trial data for Cobenfy in schizophrenia, focused on patients switching from other oral atypical antipsychotics.
-
The results highlight safety and tolerability outcomes for Cobenfy, which combines xanomeline and trospium chloride.
-
The data were presented at a major international congress as the first product-related update on switching since Cobenfy’s approval.
Bristol Myers Squibb, known primarily for its oncology and cardiovascular franchises, has been building out a neuropsychiatry portfolio that includes Cobenfy for schizophrenia. Fresh switching data matters for clinicians who often manage patients already stabilized, or partially stabilized, on other atypical antipsychotics and are weighing treatment changes.
For investors tracking NYSE:BMY, this update adds another data point on how Cobenfy might be used in everyday practice rather than only in controlled trial settings. Future clinical and real-world evidence could shape how widely Cobenfy is adopted in treatment algorithms, as psychiatrists assess its role alongside established oral antipsychotics.
Stay updated on the most important news stories for Bristol-Myers Squibb by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Bristol-Myers Squibb.
We’ve flagged 2 risks for Bristol-Myers Squibb. See which could impact your investment.
-
✅ Price vs Analyst Target: At US$58.54, BMY trades about 7% below the US$62.72 analyst target.
-
✅ Simply Wall St Valuation: Shares are described as trading 51.5% below estimated fair value.
-
❌ Recent Momentum: The 30 day return of about 6.1% decline signals weak short term sentiment.
There is only one way to know the right time to buy, sell or hold Bristol-Myers Squibb. Head to the Simply Wall St company report for the latest analysis of Bristol-Myers Squibb’s fair value.
-
📊 The new Cobenfy Phase 4 switching data can help you assess how neuropsychiatry might fit alongside BMY’s oncology and cardiovascular pillars.
-
📊 Watch uptake signals around Cobenfy, label updates, and any further real world data that clarify its use in patients moving from other atypical antipsychotics.
-
⚠️ Balance this against noted minor risks such as high debt levels and one off items that can affect how clean reported earnings appear.
For the full picture, including more risks and potential rewards, review the complete Bristol-Myers Squibb analysis. You can also visit the community page for Bristol-Myers Squibb to see how other investors interpret this latest news and its impact on the company’s narrative.